| Maintenance chemotherapy: an evolving and increasingly acceptable strategy in cancer management. | |
| | |
MedLine Citation:
|
PMID: 20711821 Owner: NLM Status: In-Process |
Abstract/OtherAbstract:
|
Individual randomized phase 3 trials and meta-analyses of previously published studies have provided support for the general concept of the clinical utility of extending the duration of antineoplastic drug therapy in an effort to prolong ("maintain") a favorable clinical state. This commentary briefly reviews data from several of these reports. |
| | |
Authors:
|
Maurie Markman |
Publication Detail:
|
Type: Journal Article |
Journal Detail:
|
Title: Current oncology reports Volume: 12 ISSN: 1534-6269 ISO Abbreviation: Curr Oncol Rep Publication Date: 2010 Nov |
Date Detail:
|
Created Date: 2010-11-03 Completed Date: - Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 100888967 Medline TA: Curr Oncol Rep Country: United States |
Other Details:
|
Languages: eng Pagination: 349-51 Citation Subset: IM |
Affiliation:
|
University of Texas M.D. Anderson Cancer Center, Houston, 77030, USA. mmarkman@mdanderson.org |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
|
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Neuro-ophthalmologic complications of syringobulbia.
Next Document: Identification of HLA-A*0201-restricted cytotoxic T lymphocyte epitope from proliferating cell nucle...